_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
Subscribe To Our Newsletter & Stay Updated
